Skip to main
PSTV
PSTV logo

PSTV Stock Forecast & Price Target

PSTV Analyst Ratings

Based on 4 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Plus Therapeutics Inc has reported a significant increase in cash and investments, rising to $16.6 million, supported by advances from the Cancer Prevention and Research Institute of Texas (CPRIT) and market activities, which has allowed the company to regain compliance with Nasdaq listing standards. The company's CNSide Diagnostic platform is demonstrating promising commercial potential, with expected revenue growth from approximately $1 million in 2025 to $38 million by 2032, underpinned by expanding manufacturing capacity and positive engagement from NCI-Designated Cancer Centers. Additionally, the successful results from the ReSPECT-LM study—highlighting a 76% radiographic response rate and a mean overall survival of 9 months—strengthen Plus Therapeutics's proposition for advancing their Phase 2 study in lung or breast cancer patients in 2026, suggesting a favorable trajectory for their product candidates.

Bears say

Plus Therapeutics Inc is facing significant financial challenges characterized by a total operating loss of $4.5 million and a net loss of $4.4 million, indicating ongoing economic strain as the company progresses through its clinical development phases. The recent grant revenue of $1.4 million suggests limited cash flow, reducing the company’s financial stability while it seeks to fund its promising but unproven cancer treatments. Furthermore, dilution resulting from an equity raise has compelled a downward adjustment of its price target, reflecting decreased investor confidence and potential market undervaluation of the company's future growth prospects.

PSTV has been analyzed by 4 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Plus Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Plus Therapeutics Inc (PSTV) Forecast

Analysts have given PSTV a Strong Buy based on their latest research and market trends.

According to 4 analysts, PSTV has a Strong Buy consensus rating as of Nov 5, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $7.75, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $7.75, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Plus Therapeutics Inc (PSTV)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.